Enlivex Therapeutics Ltd (NASDAQ:ENLV)’s traded shares stood at 0.43 million during the last session, with the company’s beta value hitting 1.13. At the close of trading, the stock’s price was $1.20, to imply an increase of 16.50% or $0.17 in intraday trading. The ENLV share’s 52-week high remains $4.59, putting it -282.5% down since that peak but still an impressive 32.5% since price per share fell to its 52-week low of $0.81.
Analysts have given a consensus recommendation of Buy for Enlivex Therapeutics Ltd (ENLV), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give ENLV a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.16.
Enlivex Therapeutics Ltd (NASDAQ:ENLV) trade information
After registering a 16.50% upside in the last session, Enlivex Therapeutics Ltd (ENLV) has traded red over the past five days. The 5-day price performance for the stock is 20.00%, and 8.21% over 30 days. With these gigs, the year-to-date price performance is 2.56%.
The extremes give us $15 and $15 for target low and target high price respectively. As such, ENLV has been trading -1150.0% off suggested target high and -1150.0% from its likely low.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 32.51% for the past 5-year period. While 2025 is set for a 58.33% return in earnings, projections for the next 5 years are at 27.68% annually.
ENLV Dividends
Enlivex Therapeutics Ltd has its next earnings report out in April. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
The next major institution holding the largest number of shares is MORGAN STANLEY with 0.24 million shares, or about 1.3077% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $0.35 million.
Going by data provided on Dec 31, 2024 , Fidelity NASDAQ Composite Index Fund holds roughly 10.42 shares. This is just over 0.06% of the total shares, with a market valuation of $12504.0
